Comparison of the Incidence of Blood Disorders in Urological Cancer Patients Undergoing Chemotherapy at Dr. Pirngadi Hospital, Medan City
Abstract
Introduction: Blood disorders such as anemia, leukopenia, and thrombocytopenia are common in urological cancer patients undergoing chemotherapy. This study aims to compare the incidence of blood disorders between patients with bladder cancer, testicular cancer, prostate cancer, and penile cancer who undergo chemotherapy at Dr. Pirngadi Hospital Medan City. Methods: This study used a retrospective design with comparative analysis. Data were taken from the medical records of patients who underwent chemotherapy during the 2019-2023 period. The sample consisted of 72 patients, namely 50 bladder cancer patients, 10 testicular cancer patients, 7 prostate cancer patients, and 5 penile cancer patients. Data were analyzed using descriptive statistical tests and analysis. Kruskal-Wallis Test. Results: showed that a decrease in hemoglobin was the most common blood disorder, especially in penile (100%) and bladder (84.6%) cancers. Leukopenia is rare, while leukocytosis is more commonly found, especially in penile cancer (60%). Platelet disorders were dominant in bladder cancer, with a decrease and increase of 12.8% each. The Kruskal-Wallis test showed no significant difference in the decrease in hemoglobin, leukocytes, or platelets between types of urological cancer (p > 0.05), except for an increase in hemoglobin which showed a significant difference (p < 0.05). Conclusions: there was no significant difference in blood disorders between types of urological cancer, although haematological monitoring remains important to prevent chemotherapy complications.
Keywords
Full Text:
PDFReferences
Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024; 384:e076743.
Giona S. The Epidemiology of Testicular Cancer. Urol Cancers. 2022; 107–16.
Zhang W, Cao G, Wu F, Wang Y, Liu Z, Hu H, et al. Global Burden of Prostate Cancer and Association with Socioeconomic Status, 1990–2019: A Systematic Analysis from the Global Burden of Disease Study. J Epidemiol Glob Health [Internet]. 2023; 13(3):407–21. Available from: https://doi.org/10.1007/s44197-023-00103-6
Study P based, Fu L, Tian T, Yao K, Chen X feng, Luo G, et al. Global Pattern and Trends in Penile Cancer Incidence: Corresponding Author: ResearchGate. 2022; 8:1–15.
Murray TBJ. The Pathogenesis of Prostate Cancer. In: Bott SRJ, Ng KL, editors. Mandala of Health. Brisbane (AU); 2021.
Dorothy A. Shead M, Tanya Fischer, MEd M, Kidney S. Kidney cancer guidelines for patients English. Int kidney cancer Coalit. 2022;
De Silva F, Alcorn J. A Tale of Two Cancers: A Current Concise Overview of Breast and Prostate Cancer. Cancers (Basel). 2022; 14(12).
Katabathina VS, Vargas-Zapata D, Monge RA, Nazarullah A, Ganeshan D, Tammisetti V, et al. Testicular germ cell tumors: Classification, pathologic features, imaging findings, and management. Radiographs. 2021; 41(6):1698–716.
Bernhard MC, Zwick A, Mohr T, Gasparoni G, Khalmurzaev O, Matveev VB, et al. The HPV and p63 status in penile cancer are linked with the infiltration and therapeutic availability of neutrophils. Mol Cancer Ther. 2021; 20(2):423–37.
Sofiani VH, Veisi P, Rukerd MRZ, Ghazi R, Nakhaie M. The complexity of human papilloma virus in cancers: a narrative review. Infect Agent Cancer [Internet]. 2023; 18(1):1–14. Available from: https://doi.org/10.1186/s13027-023-00488-w
Hu J, Chen J, Ou Z, Chen H, Liu Z, Chen M, et al. Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study. Cell Reports Med [Internet]. 2022; 3(11):100785. Available from: https://doi.org/10.1016/j.xcrm.2022.100785
Mirowski M. Drug Development. 2024;
Lawrence H. Development of Prostate Cancer Therapy. Contin med educ [Internet]. 2019; 46(8):521–7. Available from: https://journal.lppmunindra.ac.id/index.php/SAP/article/view/2731
Vale CL, Fisher DJ, Godolphin PJ, Rydzewska LH, Boher JM, Burdett S, et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. Lancet Oncol. 2023 Jul; 24(7):783–97.
Stecca CE, Alt M, Jiang DM, Chung P, Crook JM, Kulkarni GS, et al. Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature. Oncol Ther. June 2021; 9(1):21–39.
Joshi VB, Chadha J, Chahoud J. Penile cancer: Updates in systemic therapy. Asian J Urol [Internet]. 2022; 9(4):374–88. Available from: https://www.sciencedirect.com/science/article/pii/S2214388222000315
Mitchell E, Pham MH, Clay A, Sanghvi R, Pietsch S, Hsu JI, et al. The long-term effects of chemotherapy on normal blood cells. bioRxiv [Internet]. 2024 Jan 1;2024.05.20.594942. Available from: http://biorxiv.org/content/early/2024/05/21/2024.05.20.594942.abstract
Seth J, Sharma S, Leong CJ, Vaibhav V, Nelson P, Shokravi A, et al. The Use of Hematopoietic Stem Cells for Heart Failure: A Systematic Review. Vol. 25, International Journal of Molecular Sciences. 2024.
Poller WC, Nahrendorf M, Swirski FK. Hematopoiesis and Cardiovascular Disease. Circ Res. 2020; 126(8):1061–85.
Lyman GH, Kuderer NM, Aapro M. Improving outcomes of chemotherapy: established and novel options for myelotherapy in the COVID-19 era. Front Oncol. 2021; 11(July):1–11.
Febriani A, Rahmawati Y. Hematological Side Effects Due to Chemotherapy and Its Management. J Respiration. 2019; 5(1):22.
Shevchenko JA, Nazarov K V, Alshevskaya AA, Sennikov S V. Erythroid Cells as Full Participants in the Tumor Microenvironment. Vol. 24, International Journal of Molecular Sciences. 2023.
Rorimpandey NG, Rambert GI, Wowor MF. Overview of Interleukin 6 and Hepidin in Chronic Diseases That Can Cause Anemia. Med, Scope, J., 2023; 5(1):64–74.
Zhou W, Su Y, Zhang Y, Han B, Liu H, Wang X. Endothelial Cells Promote Docetaxel Resistance of Prostate Cancer Cells by Inducing ERG Expression and Activating Akt/mTOR Signaling Pathway. Front Oncol. 2020; 10(December):1–14.
Karim MU, Tisseverasinghe S, Cartes R, Martinez C, Bahoric B, Niazi T. Early Versus Delayed Androgen Deprivation Therapy for Biochemical Recurrence After Local Curative Treatment in Non-Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of the Literature. Vol. 17, Cancers. 2025.
Zhang D, Luo G, Jin K, Bao X, Huang L, Ke J. The underlying mechanisms of cisplatin-induced nephrotoxicity and its therapeutic intervention using natural compounds. Naunyn Schmiedebergs Arch Pharmacol [Internet]. 2023; 396(11):2925–41. Available from: https://doi.org/10.1007/s00210-023-02559-6
Yuliandra Y, Nasif H, Ermayanti S, Sulistyowati L, Juwita DA. Hematologic Toxicities of Chemotherapy in Lung Cancer Patients: A Retrospective Study in Dr. M. Djamil Hospital Padang, Indonesia. Indones J Clin Pharm. 2019; 8(2):129.
Bagus I, Pramana P, Hakim L, Djatisoesanto W, Hardjowijoto S. Predictive factors of bleomycin, etoposide and cisplatin chemotherapy failure in patients with testicular seminoma a retrospective cohort study. Med Udayana [Internet]. 2019; 8(6):2597–8012. Available from: https://ojs.unud.ac.id/index.php/eum
Poon DMC, Chan K, Chan TW, Ng B, Siu S, Ng J, et al. Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients. Asia Pac J Clin Oncol. 2021 Apr; 17 Suppl 3:39–47.
30. Zhang Q, Li Y, Zhang Y, Deng Z, Ding Y. Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation. World J Surg Oncol [Internet]. 2024; 22(1):50. Available from: https://doi.org/10.1186/s12957-024-03305-9
Gülle S, Çelik A, Birlik M, Yılmaz O. Skin and lung fibrosis induced by bleomycin in mice: a systematic review. Rheumatism [Internet]. 2024 Mar 22; 76(1 SE-Reviews). Available from: https://www.reumatismo.org/reuma/article/view/1642
Moik F, Ay C. Treatment of VTE in the thrombocytopenic cancer patient. Hematology [Internet]. 2024 Dec 6; 2024(1):259–69. Available from: https://doi.org/10.1182/hematology.2024000551
Tsantes AG, Petrou E, Tsante KA, Sokou R, Frantzeskaki F, Domouchtsidou A, et al. Cancer-Associated Thrombosis: Pathophysiology, Laboratory Assessment, and Current Guidelines. Vol. 16, Cancers. 2024.
Sarofah T, Ritonga F. Comparison of Blood Urea and Creatinine Levels in Patients with Chronic Kidney Failure Pre and Post Hemodialysis. A Student ... [Internet]. 2022; 4:40–4. Available from: https://journal.binawan.ac.id/index.php/bsj/article/view/214
Paradise NI. DESCRIPTION OF CREATININE AND UREA LEVELS IN PATIENTS WITH CHRONIC KIDNEY FAILURE BEFORE AND AFTER HEMODIALYSIS AT R.S.U RANGE ASAHAN SRI [Internet]. Vol. 8, T-Shirt GL Dergisi. 2020. 147–154 p. Available from: https://doi.org/10.1016/j.jnc.2020.125798%0Ahttps://doi.org/10.1016/j.smr.2020.02.002%0Ahttp://www.ncbi.nlm.nih.gov/pubmed/810049%0Ahttp://doi.wiley.com/10.1002/anie.197505391%0Ahttp://www.sciencedirect.com/science/article/pii/B9780857090409500205%0Ahttp:
Colombo G, Altomare A, Astori E, Landoni L, Garavaglia ML, Rossi R, et al. Effects of Physiological and Pathological Urea Concentrations on Human Microvascular Endothelial Cells. Vol. 24, International Journal of Molecular Sciences. 2023.
Espi M, Koppe L, Fouque D, Thaunat O. Chronic Kidney Disease-Associated Immune Dysfunctions: Impact of Protein-Bound Uremic Retention Solutes on Immune Cells. Vol. 12, Toxins. 2020.
Hutapea RD, Widaningsih Y, Mangarengi F, Muhadi D. Analysis of Urea, Creatinine, and Platelet Indices in Hypertensive Patients. Indonesia, J Clin Pathol Med Lab. 2021; 27(2):117–21.
Setiawan SD. The effect of chemotherapy on cancer patients on. pharmacon J. 2015; 10(1):94–9.
DOI: https://doi.org/10.30596/jih.v7i3.26204
Refbacks
- There are currently no refbacks.
Fakultas Kedokteran
Universitas Muhammadiyah Sumatera Utara
Jln.Gedung Arca No. 53 Medan 20217
Telp/HP/Whatsapp: +62 8112570085, +62 857-6248-0974
Website : http://jurnal.umsu.ac.id/index.php/JIH/index
Email : implementahusada@umsu.ac.id